Focus on SARS-CoV-2

SARS-CoV-2 and the clinical features of COVID-19 dramatically highlight the need to better understand why some patients are so strikingly more susceptible to a viral respiratory pathogen. Several researchers involved in RESIST are successfully working to solve this challenge. They are seeking new diagnostic methods, improving vaccines and cloning broadly neutralising monoclonal antibodies.

On this page, we have bundled publications on research related to SARS-CoV-2, as well as news related to the topic of corona infections. It also contains videos and press releases explaining the research, as well as questions and their answers about the topic. We will be happy to keep you up to date.

RESIST-News about SARS-CoV-2

  • What leads to severe COVID-19 diseases?

    February 21, 2023

    February 21, 2023

    February 21, 2023

    Team analyses genetic and epicenetic regulators: Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. But why [...]

    Team analyses genetic and epicenetic regulators: Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. But why [...]

    Team analyses genetic and epicenetic regulators: Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. But why is this the case? Unfortunately, we do not know exactly. We do know that an overactive innate immune system is [...]

  • Research with change

    February 16, 2023

    February 16, 2023

    February 16, 2023

    The Corona pandemic also turned one of the first doctoral theses produced in RESIST on its head One of the first doctoral theses produced in a RESIST project is [...]

    The Corona pandemic also turned one of the first doctoral theses produced in RESIST on its head One of the first doctoral theses produced in a RESIST project is [...]

    The Corona pandemic also turned one of the first doctoral theses produced in RESIST on its head One of the first doctoral theses produced in a RESIST project is that of Matthias Bruhn; he defended his work at the end of January 2023. The course was turbulent. At the [...]

  • COVID – and what happens next?

    January 18, 2023

    January 18, 2023

    January 18, 2023

    Professor Dr. Melanie Brinkmann and Professor Dr. Reinhold Förster summarised the past three years with SARS-CoV-2 and ventured a look into the future on 17 January at Herrenhausen Palace [...]

    Professor Dr. Melanie Brinkmann and Professor Dr. Reinhold Förster summarised the past three years with SARS-CoV-2 and ventured a look into the future on 17 January at Herrenhausen Palace [...]

    Professor Dr. Melanie Brinkmann and Professor Dr. Reinhold Förster summarised the past three years with SARS-CoV-2 and ventured a look into the future on 17 January at Herrenhausen Palace as part of Herrenhausen Late. Looking back, they recalled the first warning from Chinese doctor Li Wengliang, who recognised the [...]

  • Covid-19 pandemic: (no) end in sight?

    January 2, 2023

    January 2, 2023

    January 2, 2023

    2 January 2023 Join us, it's going to be exciting: On the evening of 17 January from 8.30 p.m., Professor Brinkmann and Professor Förster will discuss with the audience [...]

    2 January 2023 Join us, it's going to be exciting: On the evening of 17 January from 8.30 p.m., Professor Brinkmann and Professor Förster will discuss with the audience [...]

    2 January 2023 Join us, it's going to be exciting: On the evening of 17 January from 8.30 p.m., Professor Brinkmann and Professor Förster will discuss with the audience lessons learned from the pandemic - and how we can better prepare ourselves in the future - as part of [...]

  • Corona research: What can the top five do?

    July 6, 2022

    July 6, 2022

    July 6, 2022

    Team investigates approaches for new drugs that act against many different coronaviruses: Finding active agents against SARS-CoV-2 and, if possible, against other coronaviruses - this is the goal that [...]

    Team investigates approaches for new drugs that act against many different coronaviruses: Finding active agents against SARS-CoV-2 and, if possible, against other coronaviruses - this is the goal that [...]

    Team investigates approaches for new drugs that act against many different coronaviruses: Finding active agents against SARS-CoV-2 and, if possible, against other coronaviruses - this is the goal that a team led by RESIST-Speaker Prof. Schulz, Institute of Virology at the Hannover Medical School (MHH) and coordinator of two [...]

  • Research on COVID-19

    March 31, 2022

    March 31, 2022

    March 31, 2022

    What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order [...]

    What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order [...]

    What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order to be able to answer them, the "COVID-19 Research Network Lower Saxony" (COFONI) is funding 13 projects with a total [...]

  • RESIST researchers lead COFONI projects

    February 1, 2022

    February 1, 2022

    February 1, 2022

    The COVID-19 Research Network Lower Saxony (COFONI) is funding 13 projects with a total of around 6 million euros. Six of these projects are led by scientists who also [...]

    The COVID-19 Research Network Lower Saxony (COFONI) is funding 13 projects with a total of around 6 million euros. Six of these projects are led by scientists who also [...]

    The COVID-19 Research Network Lower Saxony (COFONI) is funding 13 projects with a total of around 6 million euros. Six of these projects are led by scientists who also conduct research in RESIST. The projects are funded with up to 500,000 euros each. In addition, RESIST researchers are also [...]

  • Corona pandemic: Prof. Falk and Prof. Meyer-Hermann are members of the expert council

    December 20, 2021

    December 20, 2021

    December 20, 2021

    In order to effectively combat the corona pandemic, the German government has set up a scientific expert council to advise it on the basis of current scientific findings on [...]

    In order to effectively combat the corona pandemic, the German government has set up a scientific expert council to advise it on the basis of current scientific findings on [...]

    In order to effectively combat the corona pandemic, the German government has set up a scientific expert council to advise it on the basis of current scientific findings on the COVID-19 pandemic and its consequences. Prof. Falk (MHH) and Prof. Meyer-Hermann (HZI) are also members of this 19-member panel. [...]

  • The third dose

    November 17, 2021

    November 17, 2021

    November 17, 2021

    The third vaccination ‚Äď is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as [...]

    The third vaccination ‚Äď is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as [...]

    The third vaccination ‚Äď is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as protection against Corona. Prof. Schulz, do we need a third vaccination? And if so, for whom and when? Yes. In [...]

  • Study on SARS-CoV-2: Cross-vaccination protects effectively

    July 15, 2021

    July 15, 2021

    July 15, 2021

    Combination of vaccines from AstraZeneca and Biontech/Pfizer protects particularly well - even with virus variants The Standing Committee on Vaccination (STIKO) supports a second vaccination with an mRNA vaccine [...]

    Combination of vaccines from AstraZeneca and Biontech/Pfizer protects particularly well - even with virus variants The Standing Committee on Vaccination (STIKO) supports a second vaccination with an mRNA vaccine [...]

    Combination of vaccines from AstraZeneca and Biontech/Pfizer protects particularly well - even with virus variants The Standing Committee on Vaccination (STIKO) supports a second vaccination with an mRNA vaccine such as the one from Biontech/Pfizer for people under 60 who have already received an AstraZeneca vaccination ‚Äď based on [...]

  • The third dose

    June 9, 2021

    June 9, 2021

    June 9, 2021

    How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one [...]

    How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one [...]

    How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one protected against SARS-CoV-2 after the double vaccination? This is not clear yet and can vary greatly between different individuals, as [...]

  • RESIST team investigates antibiotic resistance

    April 14, 2021

    April 14, 2021

    April 14, 2021

    The impact of the COVID-19 pandemic on multidrug-resistant pathogens: How do the hygiene and distance rules introduced due to the pandemic influence the transmission of multidrug-resistant pathogens in hospitals? [...]

    The impact of the COVID-19 pandemic on multidrug-resistant pathogens: How do the hygiene and distance rules introduced due to the pandemic influence the transmission of multidrug-resistant pathogens in hospitals? [...]

    The impact of the COVID-19 pandemic on multidrug-resistant pathogens: How do the hygiene and distance rules introduced due to the pandemic influence the transmission of multidrug-resistant pathogens in hospitals? Professor Dr Marco Galardini and Professor Dr Susanne Häußler are investigating this question in a new three-year project. The DFG [...]

  • Mutations of the SARS-CoV-2 coronavirus: Professor Schulz answered questions

    February 9, 2021

    February 9, 2021

    February 9, 2021

    Mutations of the SARS-CoV-2 coronavirus are on everyone's mind these days. Professor Schulz, there are British, South African and Brazilian variants of the SARS-CoV-2 coronavirus in Germany. How dangerous [...]

    Mutations of the SARS-CoV-2 coronavirus are on everyone's mind these days. Professor Schulz, there are British, South African and Brazilian variants of the SARS-CoV-2 coronavirus in Germany. How dangerous [...]

    Mutations of the SARS-CoV-2 coronavirus are on everyone's mind these days. Professor Schulz, there are British, South African and Brazilian variants of the SARS-CoV-2 coronavirus in Germany. How dangerous are these variants? In the case of the English variant called B.1.1.7, it is relatively certain that it is more [...]

  • Corona pandemic: explained to the public

    January 13, 2021

    January 13, 2021

    January 13, 2021

    RESIST researchers are not only busy doing research on SARS-CoV-2 at this time, but also explaining it. For example, on 11 January, RESIST speaker Professor Schulz explained facts about [...]

    RESIST researchers are not only busy doing research on SARS-CoV-2 at this time, but also explaining it. For example, on 11 January, RESIST speaker Professor Schulz explained facts about [...]

    RESIST researchers are not only busy doing research on SARS-CoV-2 at this time, but also explaining it. For example, on 11 January, RESIST speaker Professor Schulz explained facts about mutated variants of the coronavirus for a feature on NDR television's Visite / Medizin editorial team. Lars Steinbr√ľck from the [...]

  • Together against the Corona pandemic

    December 4, 2020

    December 4, 2020

    December 4, 2020

    RESIST researchers are part of the Network of University Medicine: To better tackle the corona pandemic the German university hospitals have joined forces by establishing the "Network of University [...]

    RESIST researchers are part of the Network of University Medicine: To better tackle the corona pandemic the German university hospitals have joined forces by establishing the "Network of University [...]

    RESIST researchers are part of the Network of University Medicine: To better tackle the corona pandemic the German university hospitals have joined forces by establishing the "Network of University Medicine". The Federal Ministry of Education and Research (BMBF) is supporting 13 projects of this network with a total of [...]

  • SARS-CoV-2: Recovered but not protected

    November 5, 2020

    November 5, 2020

    November 5, 2020

    Simple test developed for detection of protective neutralising antibodies: Infections with the coronavirus SARS-CoV-2 can take very different courses. While some people have no symptoms, others get seriously ill. [...]

    Simple test developed for detection of protective neutralising antibodies: Infections with the coronavirus SARS-CoV-2 can take very different courses. While some people have no symptoms, others get seriously ill. [...]

    Simple test developed for detection of protective neutralising antibodies: Infections with the coronavirus SARS-CoV-2 can take very different courses. While some people have no symptoms, others get seriously ill. An important question that often arises after surviving an infection is whether neutralising antibodies against the virus have been generated. [...]

  • COVID-19: T lymphocytes play an important role

    July 17, 2020

    July 17, 2020

    July 17, 2020

    A team from Hannover Medical School, which also includes RESIST researchers, publishes the first European study of this kind in the Lancet journal "EBioMedicine‚ÄĚ / The course of infection [...]

    A team from Hannover Medical School, which also includes RESIST researchers, publishes the first European study of this kind in the Lancet journal "EBioMedicine‚ÄĚ / The course of infection [...]

    A team from Hannover Medical School, which also includes RESIST researchers, publishes the first European study of this kind in the Lancet journal "EBioMedicine‚ÄĚ / The course of infection with the coronavirus SARS-CoV-2 can progress very differently - some people recover completely without symptoms or show a mild course [...]

  • After a ‚Äúcorona break‚ÄĚ: Recruitment of RESIST cohort resumed

    June 22, 2020

    June 22, 2020

    June 22, 2020

    SARS-CoV-2 has made it very clear to us: As we age, the defense by our immune system against viruses can be very poor sometimes. Unfortunately, also vaccinations show often [...]

    SARS-CoV-2 has made it very clear to us: As we age, the defense by our immune system against viruses can be very poor sometimes. Unfortunately, also vaccinations show often [...]

    SARS-CoV-2 has made it very clear to us: As we age, the defense by our immune system against viruses can be very poor sometimes. Unfortunately, also vaccinations show often only weak effects in elderly individuals and infections can progress more severely than in younger people. Why is that? In [...]

  • SARS-CoV-2: This is what the RESIST teams are working on

    May 26, 2020

    May 26, 2020

    May 26, 2020

    Numerous RESIST scientists in the various institutions have expanded their work and are now also focusing on SARS-CoV-2: Professor Dr. Luka ńĆińćin-҆ain at the HZI is developing new technologies [...]

    Numerous RESIST scientists in the various institutions have expanded their work and are now also focusing on SARS-CoV-2: Professor Dr. Luka ńĆińćin-҆ain at the HZI is developing new technologies [...]

    Numerous RESIST scientists in the various institutions have expanded their work and are now also focusing on SARS-CoV-2: Professor Dr. Luka ńĆińćin-҆ain at the HZI is developing new technologies for improved serological virus diagnostics, for vaccine development and for identification of antiviral molecules against SARS-CoV-2. His team also works [...]

  • Particularly potent antibodies should help against SARS-CoV-2

    May 18, 2020

    May 18, 2020

    May 18, 2020

    People who have successfully mastered an infection with SARS-CoV-2 have various protective antibodies in their blood. Some of these substances are particularly effective. Detecting these highly potent antibodies, producing [...]

    People who have successfully mastered an infection with SARS-CoV-2 have various protective antibodies in their blood. Some of these substances are particularly effective. Detecting these highly potent antibodies, producing [...]

    People who have successfully mastered an infection with SARS-CoV-2 have various protective antibodies in their blood. Some of these substances are particularly effective. Detecting these highly potent antibodies, producing them genetically in the laboratory and then using them to protect against infection and to treat the disease ‚Äď this [...]

  • With smallpox vaccination vector against the new Coronavirus

    May 15, 2020

    May 15, 2020

    May 15, 2020

    In his search for a suitable vaccine against the coronavirus SARS-CoV-2, Professor F√∂rster relies on old friends. In cooperation with the Ludwig-Maximilians-Universit√§t M√ľnchen (LMU), the co-speaker of RESIST is [...]

    In his search for a suitable vaccine against the coronavirus SARS-CoV-2, Professor F√∂rster relies on old friends. In cooperation with the Ludwig-Maximilians-Universit√§t M√ľnchen (LMU), the co-speaker of RESIST is [...]

    In his search for a suitable vaccine against the coronavirus SARS-CoV-2, Professor F√∂rster relies on old friends. In cooperation with the Ludwig-Maximilians-Universit√§t M√ľnchen (LMU), the co-speaker of RESIST is testing a promising vaccine based on a smallpox virus. The Modified Vaccinia Virus Ankara (MVA) has been used as a [...]

  • RESIST-Research on the coronavirus SARS-CoV-2

    April 17, 2020

    April 17, 2020

    April 17, 2020

    Many different research projects on SARS-CoV-2 are carried out in the Cluster of Excellence RESIST - always with the aim of protecting and treating people in the best possible [...]

    Many different research projects on SARS-CoV-2 are carried out in the Cluster of Excellence RESIST - always with the aim of protecting and treating people in the best possible [...]

    Many different research projects on SARS-CoV-2 are carried out in the Cluster of Excellence RESIST - always with the aim of protecting and treating people in the best possible way. Professor Schulz gives an overview of the work: Professor Schulz, what are RESIST scientists researching with regard to SARS-CoV-2? [...]

  • What leads to severe COVID-19 diseases?

    February 21, 2023

    February 21, 2023

    February 21, 2023

    Team analyses genetic and epicenetic regulators: Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. But why [...]

    Team analyses genetic and epicenetic regulators: Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. But why [...]

    Team analyses genetic and epicenetic regulators: Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. But why is this the case? Unfortunately, we do not know exactly. We do know that an overactive innate immune system is [...]

  • Research with change

    February 16, 2023

    February 16, 2023

    February 16, 2023

    The Corona pandemic also turned one of the first doctoral theses produced in RESIST on its head One of the first doctoral theses produced in a RESIST project is [...]

    The Corona pandemic also turned one of the first doctoral theses produced in RESIST on its head One of the first doctoral theses produced in a RESIST project is [...]

    The Corona pandemic also turned one of the first doctoral theses produced in RESIST on its head One of the first doctoral theses produced in a RESIST project is that of Matthias Bruhn; he defended his work at the end of January 2023. The course was turbulent. At the [...]

  • COVID – and what happens next?

    January 18, 2023

    January 18, 2023

    January 18, 2023

    Professor Dr. Melanie Brinkmann and Professor Dr. Reinhold Förster summarised the past three years with SARS-CoV-2 and ventured a look into the future on 17 January at Herrenhausen Palace [...]

    Professor Dr. Melanie Brinkmann and Professor Dr. Reinhold Förster summarised the past three years with SARS-CoV-2 and ventured a look into the future on 17 January at Herrenhausen Palace [...]

    Professor Dr. Melanie Brinkmann and Professor Dr. Reinhold Förster summarised the past three years with SARS-CoV-2 and ventured a look into the future on 17 January at Herrenhausen Palace as part of Herrenhausen Late. Looking back, they recalled the first warning from Chinese doctor Li Wengliang, who recognised the [...]

  • Covid-19 pandemic: (no) end in sight?

    January 2, 2023

    January 2, 2023

    January 2, 2023

    2 January 2023 Join us, it's going to be exciting: On the evening of 17 January from 8.30 p.m., Professor Brinkmann and Professor Förster will discuss with the audience [...]

    2 January 2023 Join us, it's going to be exciting: On the evening of 17 January from 8.30 p.m., Professor Brinkmann and Professor Förster will discuss with the audience [...]

    2 January 2023 Join us, it's going to be exciting: On the evening of 17 January from 8.30 p.m., Professor Brinkmann and Professor Förster will discuss with the audience lessons learned from the pandemic - and how we can better prepare ourselves in the future - as part of [...]

  • Corona research: What can the top five do?

    July 6, 2022

    July 6, 2022

    July 6, 2022

    Team investigates approaches for new drugs that act against many different coronaviruses: Finding active agents against SARS-CoV-2 and, if possible, against other coronaviruses - this is the goal that [...]

    Team investigates approaches for new drugs that act against many different coronaviruses: Finding active agents against SARS-CoV-2 and, if possible, against other coronaviruses - this is the goal that [...]

    Team investigates approaches for new drugs that act against many different coronaviruses: Finding active agents against SARS-CoV-2 and, if possible, against other coronaviruses - this is the goal that a team led by RESIST-Speaker Prof. Schulz, Institute of Virology at the Hannover Medical School (MHH) and coordinator of two [...]

  • Research on COVID-19

    March 31, 2022

    March 31, 2022

    March 31, 2022

    What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order [...]

    What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order [...]

    What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order to be able to answer them, the "COVID-19 Research Network Lower Saxony" (COFONI) is funding 13 projects with a total [...]

  • RESIST researchers lead COFONI projects

    February 1, 2022

    February 1, 2022

    February 1, 2022

    The COVID-19 Research Network Lower Saxony (COFONI) is funding 13 projects with a total of around 6 million euros. Six of these projects are led by scientists who also [...]

    The COVID-19 Research Network Lower Saxony (COFONI) is funding 13 projects with a total of around 6 million euros. Six of these projects are led by scientists who also [...]

    The COVID-19 Research Network Lower Saxony (COFONI) is funding 13 projects with a total of around 6 million euros. Six of these projects are led by scientists who also conduct research in RESIST. The projects are funded with up to 500,000 euros each. In addition, RESIST researchers are also [...]

  • Corona pandemic: Prof. Falk and Prof. Meyer-Hermann are members of the expert council

    December 20, 2021

    December 20, 2021

    December 20, 2021

    In order to effectively combat the corona pandemic, the German government has set up a scientific expert council to advise it on the basis of current scientific findings on [...]

    In order to effectively combat the corona pandemic, the German government has set up a scientific expert council to advise it on the basis of current scientific findings on [...]

    In order to effectively combat the corona pandemic, the German government has set up a scientific expert council to advise it on the basis of current scientific findings on the COVID-19 pandemic and its consequences. Prof. Falk (MHH) and Prof. Meyer-Hermann (HZI) are also members of this 19-member panel. [...]

  • The third dose

    November 17, 2021

    November 17, 2021

    November 17, 2021

    The third vaccination ‚Äď is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as [...]

    The third vaccination ‚Äď is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as [...]

    The third vaccination ‚Äď is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as protection against Corona. Prof. Schulz, do we need a third vaccination? And if so, for whom and when? Yes. In [...]

  • Study on SARS-CoV-2: Cross-vaccination protects effectively

    July 15, 2021

    July 15, 2021

    July 15, 2021

    Combination of vaccines from AstraZeneca and Biontech/Pfizer protects particularly well - even with virus variants The Standing Committee on Vaccination (STIKO) supports a second vaccination with an mRNA vaccine [...]

    Combination of vaccines from AstraZeneca and Biontech/Pfizer protects particularly well - even with virus variants The Standing Committee on Vaccination (STIKO) supports a second vaccination with an mRNA vaccine [...]

    Combination of vaccines from AstraZeneca and Biontech/Pfizer protects particularly well - even with virus variants The Standing Committee on Vaccination (STIKO) supports a second vaccination with an mRNA vaccine such as the one from Biontech/Pfizer for people under 60 who have already received an AstraZeneca vaccination ‚Äď based on [...]

  • The third dose

    June 9, 2021

    June 9, 2021

    June 9, 2021

    How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one [...]

    How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one [...]

    How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one protected against SARS-CoV-2 after the double vaccination? This is not clear yet and can vary greatly between different individuals, as [...]

  • RESIST team investigates antibiotic resistance

    April 14, 2021

    April 14, 2021

    April 14, 2021

    The impact of the COVID-19 pandemic on multidrug-resistant pathogens: How do the hygiene and distance rules introduced due to the pandemic influence the transmission of multidrug-resistant pathogens in hospitals? [...]

    The impact of the COVID-19 pandemic on multidrug-resistant pathogens: How do the hygiene and distance rules introduced due to the pandemic influence the transmission of multidrug-resistant pathogens in hospitals? [...]

    The impact of the COVID-19 pandemic on multidrug-resistant pathogens: How do the hygiene and distance rules introduced due to the pandemic influence the transmission of multidrug-resistant pathogens in hospitals? Professor Dr Marco Galardini and Professor Dr Susanne Häußler are investigating this question in a new three-year project. The DFG [...]

  • Mutations of the SARS-CoV-2 coronavirus: Professor Schulz answered questions

    February 9, 2021

    February 9, 2021

    February 9, 2021

    Mutations of the SARS-CoV-2 coronavirus are on everyone's mind these days. Professor Schulz, there are British, South African and Brazilian variants of the SARS-CoV-2 coronavirus in Germany. How dangerous [...]

    Mutations of the SARS-CoV-2 coronavirus are on everyone's mind these days. Professor Schulz, there are British, South African and Brazilian variants of the SARS-CoV-2 coronavirus in Germany. How dangerous [...]

    Mutations of the SARS-CoV-2 coronavirus are on everyone's mind these days. Professor Schulz, there are British, South African and Brazilian variants of the SARS-CoV-2 coronavirus in Germany. How dangerous are these variants? In the case of the English variant called B.1.1.7, it is relatively certain that it is more [...]

  • Corona pandemic: explained to the public

    January 13, 2021

    January 13, 2021

    January 13, 2021

    RESIST researchers are not only busy doing research on SARS-CoV-2 at this time, but also explaining it. For example, on 11 January, RESIST speaker Professor Schulz explained facts about [...]

    RESIST researchers are not only busy doing research on SARS-CoV-2 at this time, but also explaining it. For example, on 11 January, RESIST speaker Professor Schulz explained facts about [...]

    RESIST researchers are not only busy doing research on SARS-CoV-2 at this time, but also explaining it. For example, on 11 January, RESIST speaker Professor Schulz explained facts about mutated variants of the coronavirus for a feature on NDR television's Visite / Medizin editorial team. Lars Steinbr√ľck from the [...]

  • Together against the Corona pandemic

    December 4, 2020

    December 4, 2020

    December 4, 2020

    RESIST researchers are part of the Network of University Medicine: To better tackle the corona pandemic the German university hospitals have joined forces by establishing the "Network of University [...]

    RESIST researchers are part of the Network of University Medicine: To better tackle the corona pandemic the German university hospitals have joined forces by establishing the "Network of University [...]

    RESIST researchers are part of the Network of University Medicine: To better tackle the corona pandemic the German university hospitals have joined forces by establishing the "Network of University Medicine". The Federal Ministry of Education and Research (BMBF) is supporting 13 projects of this network with a total of [...]

  • SARS-CoV-2: Recovered but not protected

    November 5, 2020

    November 5, 2020

    November 5, 2020

    Simple test developed for detection of protective neutralising antibodies: Infections with the coronavirus SARS-CoV-2 can take very different courses. While some people have no symptoms, others get seriously ill. [...]

    Simple test developed for detection of protective neutralising antibodies: Infections with the coronavirus SARS-CoV-2 can take very different courses. While some people have no symptoms, others get seriously ill. [...]

    Simple test developed for detection of protective neutralising antibodies: Infections with the coronavirus SARS-CoV-2 can take very different courses. While some people have no symptoms, others get seriously ill. An important question that often arises after surviving an infection is whether neutralising antibodies against the virus have been generated. [...]

  • COVID-19: T lymphocytes play an important role

    July 17, 2020

    July 17, 2020

    July 17, 2020

    A team from Hannover Medical School, which also includes RESIST researchers, publishes the first European study of this kind in the Lancet journal "EBioMedicine‚ÄĚ / The course of infection [...]

    A team from Hannover Medical School, which also includes RESIST researchers, publishes the first European study of this kind in the Lancet journal "EBioMedicine‚ÄĚ / The course of infection [...]

    A team from Hannover Medical School, which also includes RESIST researchers, publishes the first European study of this kind in the Lancet journal "EBioMedicine‚ÄĚ / The course of infection with the coronavirus SARS-CoV-2 can progress very differently - some people recover completely without symptoms or show a mild course [...]

  • After a ‚Äúcorona break‚ÄĚ: Recruitment of RESIST cohort resumed

    June 22, 2020

    June 22, 2020

    June 22, 2020

    SARS-CoV-2 has made it very clear to us: As we age, the defense by our immune system against viruses can be very poor sometimes. Unfortunately, also vaccinations show often [...]

    SARS-CoV-2 has made it very clear to us: As we age, the defense by our immune system against viruses can be very poor sometimes. Unfortunately, also vaccinations show often [...]

    SARS-CoV-2 has made it very clear to us: As we age, the defense by our immune system against viruses can be very poor sometimes. Unfortunately, also vaccinations show often only weak effects in elderly individuals and infections can progress more severely than in younger people. Why is that? In [...]

  • SARS-CoV-2: This is what the RESIST teams are working on

    May 26, 2020

    May 26, 2020

    May 26, 2020

    Numerous RESIST scientists in the various institutions have expanded their work and are now also focusing on SARS-CoV-2: Professor Dr. Luka ńĆińćin-҆ain at the HZI is developing new technologies [...]

    Numerous RESIST scientists in the various institutions have expanded their work and are now also focusing on SARS-CoV-2: Professor Dr. Luka ńĆińćin-҆ain at the HZI is developing new technologies [...]

    Numerous RESIST scientists in the various institutions have expanded their work and are now also focusing on SARS-CoV-2: Professor Dr. Luka ńĆińćin-҆ain at the HZI is developing new technologies for improved serological virus diagnostics, for vaccine development and for identification of antiviral molecules against SARS-CoV-2. His team also works [...]

  • Particularly potent antibodies should help against SARS-CoV-2

    May 18, 2020

    May 18, 2020

    May 18, 2020

    People who have successfully mastered an infection with SARS-CoV-2 have various protective antibodies in their blood. Some of these substances are particularly effective. Detecting these highly potent antibodies, producing [...]

    People who have successfully mastered an infection with SARS-CoV-2 have various protective antibodies in their blood. Some of these substances are particularly effective. Detecting these highly potent antibodies, producing [...]

    People who have successfully mastered an infection with SARS-CoV-2 have various protective antibodies in their blood. Some of these substances are particularly effective. Detecting these highly potent antibodies, producing them genetically in the laboratory and then using them to protect against infection and to treat the disease ‚Äď this [...]

  • With smallpox vaccination vector against the new Coronavirus

    May 15, 2020

    May 15, 2020

    May 15, 2020

    In his search for a suitable vaccine against the coronavirus SARS-CoV-2, Professor F√∂rster relies on old friends. In cooperation with the Ludwig-Maximilians-Universit√§t M√ľnchen (LMU), the co-speaker of RESIST is [...]

    In his search for a suitable vaccine against the coronavirus SARS-CoV-2, Professor F√∂rster relies on old friends. In cooperation with the Ludwig-Maximilians-Universit√§t M√ľnchen (LMU), the co-speaker of RESIST is [...]

    In his search for a suitable vaccine against the coronavirus SARS-CoV-2, Professor F√∂rster relies on old friends. In cooperation with the Ludwig-Maximilians-Universit√§t M√ľnchen (LMU), the co-speaker of RESIST is testing a promising vaccine based on a smallpox virus. The Modified Vaccinia Virus Ankara (MVA) has been used as a [...]

  • RESIST-Research on the coronavirus SARS-CoV-2

    April 17, 2020

    April 17, 2020

    April 17, 2020

    Many different research projects on SARS-CoV-2 are carried out in the Cluster of Excellence RESIST - always with the aim of protecting and treating people in the best possible [...]

    Many different research projects on SARS-CoV-2 are carried out in the Cluster of Excellence RESIST - always with the aim of protecting and treating people in the best possible [...]

    Many different research projects on SARS-CoV-2 are carried out in the Cluster of Excellence RESIST - always with the aim of protecting and treating people in the best possible way. Professor Schulz gives an overview of the work: Professor Schulz, what are RESIST scientists researching with regard to SARS-CoV-2? [...]

  • What leads to severe COVID-19 diseases?

    February 21, 2023

    February 21, 2023

    February 21, 2023

    Team analyses genetic and epicenetic regulators: Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. But why [...]

    Team analyses genetic and epicenetic regulators: Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. But why [...]

    Team analyses genetic and epicenetic regulators: Infection with SARS-CoV-2 leads to severe disease in some people, whereas others do not get ill or only experience mild disease. But why is this the case? Unfortunately, we do not know exactly. We do know that an overactive innate immune system is [...]

  • Research with change

    February 16, 2023

    February 16, 2023

    February 16, 2023

    The Corona pandemic also turned one of the first doctoral theses produced in RESIST on its head One of the first doctoral theses produced in a RESIST project is [...]

    The Corona pandemic also turned one of the first doctoral theses produced in RESIST on its head One of the first doctoral theses produced in a RESIST project is [...]

    The Corona pandemic also turned one of the first doctoral theses produced in RESIST on its head One of the first doctoral theses produced in a RESIST project is that of Matthias Bruhn; he defended his work at the end of January 2023. The course was turbulent. At the [...]

  • COVID – and what happens next?

    January 18, 2023

    January 18, 2023

    January 18, 2023

    Professor Dr. Melanie Brinkmann and Professor Dr. Reinhold Förster summarised the past three years with SARS-CoV-2 and ventured a look into the future on 17 January at Herrenhausen Palace [...]

    Professor Dr. Melanie Brinkmann and Professor Dr. Reinhold Förster summarised the past three years with SARS-CoV-2 and ventured a look into the future on 17 January at Herrenhausen Palace [...]

    Professor Dr. Melanie Brinkmann and Professor Dr. Reinhold Förster summarised the past three years with SARS-CoV-2 and ventured a look into the future on 17 January at Herrenhausen Palace as part of Herrenhausen Late. Looking back, they recalled the first warning from Chinese doctor Li Wengliang, who recognised the [...]

  • Covid-19 pandemic: (no) end in sight?

    January 2, 2023

    January 2, 2023

    January 2, 2023

    2 January 2023 Join us, it's going to be exciting: On the evening of 17 January from 8.30 p.m., Professor Brinkmann and Professor Förster will discuss with the audience [...]

    2 January 2023 Join us, it's going to be exciting: On the evening of 17 January from 8.30 p.m., Professor Brinkmann and Professor Förster will discuss with the audience [...]

    2 January 2023 Join us, it's going to be exciting: On the evening of 17 January from 8.30 p.m., Professor Brinkmann and Professor Förster will discuss with the audience lessons learned from the pandemic - and how we can better prepare ourselves in the future - as part of [...]

  • Corona research: What can the top five do?

    July 6, 2022

    July 6, 2022

    July 6, 2022

    Team investigates approaches for new drugs that act against many different coronaviruses: Finding active agents against SARS-CoV-2 and, if possible, against other coronaviruses - this is the goal that [...]

    Team investigates approaches for new drugs that act against many different coronaviruses: Finding active agents against SARS-CoV-2 and, if possible, against other coronaviruses - this is the goal that [...]

    Team investigates approaches for new drugs that act against many different coronaviruses: Finding active agents against SARS-CoV-2 and, if possible, against other coronaviruses - this is the goal that a team led by RESIST-Speaker Prof. Schulz, Institute of Virology at the Hannover Medical School (MHH) and coordinator of two [...]

  • Research on COVID-19

    March 31, 2022

    March 31, 2022

    March 31, 2022

    What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order [...]

    What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order [...]

    What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order to be able to answer them, the "COVID-19 Research Network Lower Saxony" (COFONI) is funding 13 projects with a total [...]

  • RESIST researchers lead COFONI projects

    February 1, 2022

    February 1, 2022

    February 1, 2022

    The COVID-19 Research Network Lower Saxony (COFONI) is funding 13 projects with a total of around 6 million euros. Six of these projects are led by scientists who also [...]

    The COVID-19 Research Network Lower Saxony (COFONI) is funding 13 projects with a total of around 6 million euros. Six of these projects are led by scientists who also [...]

    The COVID-19 Research Network Lower Saxony (COFONI) is funding 13 projects with a total of around 6 million euros. Six of these projects are led by scientists who also conduct research in RESIST. The projects are funded with up to 500,000 euros each. In addition, RESIST researchers are also [...]

  • Corona pandemic: Prof. Falk and Prof. Meyer-Hermann are members of the expert council

    December 20, 2021

    December 20, 2021

    December 20, 2021

    In order to effectively combat the corona pandemic, the German government has set up a scientific expert council to advise it on the basis of current scientific findings on [...]

    In order to effectively combat the corona pandemic, the German government has set up a scientific expert council to advise it on the basis of current scientific findings on [...]

    In order to effectively combat the corona pandemic, the German government has set up a scientific expert council to advise it on the basis of current scientific findings on the COVID-19 pandemic and its consequences. Prof. Falk (MHH) and Prof. Meyer-Hermann (HZI) are also members of this 19-member panel. [...]

  • The third dose

    November 17, 2021

    November 17, 2021

    November 17, 2021

    The third vaccination ‚Äď is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as [...]

    The third vaccination ‚Äď is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as [...]

    The third vaccination ‚Äď is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as protection against Corona. Prof. Schulz, do we need a third vaccination? And if so, for whom and when? Yes. In [...]

  • Study on SARS-CoV-2: Cross-vaccination protects effectively

    July 15, 2021

    July 15, 2021

    July 15, 2021

    Combination of vaccines from AstraZeneca and Biontech/Pfizer protects particularly well - even with virus variants The Standing Committee on Vaccination (STIKO) supports a second vaccination with an mRNA vaccine [...]

    Combination of vaccines from AstraZeneca and Biontech/Pfizer protects particularly well - even with virus variants The Standing Committee on Vaccination (STIKO) supports a second vaccination with an mRNA vaccine [...]

    Combination of vaccines from AstraZeneca and Biontech/Pfizer protects particularly well - even with virus variants The Standing Committee on Vaccination (STIKO) supports a second vaccination with an mRNA vaccine such as the one from Biontech/Pfizer for people under 60 who have already received an AstraZeneca vaccination ‚Äď based on [...]

  • The third dose

    June 9, 2021

    June 9, 2021

    June 9, 2021

    How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one [...]

    How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one [...]

    How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one protected against SARS-CoV-2 after the double vaccination? This is not clear yet and can vary greatly between different individuals, as [...]

  • RESIST team investigates antibiotic resistance

    April 14, 2021

    April 14, 2021

    April 14, 2021

    The impact of the COVID-19 pandemic on multidrug-resistant pathogens: How do the hygiene and distance rules introduced due to the pandemic influence the transmission of multidrug-resistant pathogens in hospitals? [...]

    The impact of the COVID-19 pandemic on multidrug-resistant pathogens: How do the hygiene and distance rules introduced due to the pandemic influence the transmission of multidrug-resistant pathogens in hospitals? [...]

    The impact of the COVID-19 pandemic on multidrug-resistant pathogens: How do the hygiene and distance rules introduced due to the pandemic influence the transmission of multidrug-resistant pathogens in hospitals? Professor Dr Marco Galardini and Professor Dr Susanne Häußler are investigating this question in a new three-year project. The DFG [...]

  • Mutations of the SARS-CoV-2 coronavirus: Professor Schulz answered questions

    February 9, 2021

    February 9, 2021

    February 9, 2021

    Mutations of the SARS-CoV-2 coronavirus are on everyone's mind these days. Professor Schulz, there are British, South African and Brazilian variants of the SARS-CoV-2 coronavirus in Germany. How dangerous [...]

    Mutations of the SARS-CoV-2 coronavirus are on everyone's mind these days. Professor Schulz, there are British, South African and Brazilian variants of the SARS-CoV-2 coronavirus in Germany. How dangerous [...]

    Mutations of the SARS-CoV-2 coronavirus are on everyone's mind these days. Professor Schulz, there are British, South African and Brazilian variants of the SARS-CoV-2 coronavirus in Germany. How dangerous are these variants? In the case of the English variant called B.1.1.7, it is relatively certain that it is more [...]

  • Corona pandemic: explained to the public

    January 13, 2021

    January 13, 2021

    January 13, 2021

    RESIST researchers are not only busy doing research on SARS-CoV-2 at this time, but also explaining it. For example, on 11 January, RESIST speaker Professor Schulz explained facts about [...]

    RESIST researchers are not only busy doing research on SARS-CoV-2 at this time, but also explaining it. For example, on 11 January, RESIST speaker Professor Schulz explained facts about [...]

    RESIST researchers are not only busy doing research on SARS-CoV-2 at this time, but also explaining it. For example, on 11 January, RESIST speaker Professor Schulz explained facts about mutated variants of the coronavirus for a feature on NDR television's Visite / Medizin editorial team. Lars Steinbr√ľck from the [...]

  • Together against the Corona pandemic

    December 4, 2020

    December 4, 2020

    December 4, 2020

    RESIST researchers are part of the Network of University Medicine: To better tackle the corona pandemic the German university hospitals have joined forces by establishing the "Network of University [...]

    RESIST researchers are part of the Network of University Medicine: To better tackle the corona pandemic the German university hospitals have joined forces by establishing the "Network of University [...]

    RESIST researchers are part of the Network of University Medicine: To better tackle the corona pandemic the German university hospitals have joined forces by establishing the "Network of University Medicine". The Federal Ministry of Education and Research (BMBF) is supporting 13 projects of this network with a total of [...]

  • SARS-CoV-2: Recovered but not protected

    November 5, 2020

    November 5, 2020

    November 5, 2020

    Simple test developed for detection of protective neutralising antibodies: Infections with the coronavirus SARS-CoV-2 can take very different courses. While some people have no symptoms, others get seriously ill. [...]

    Simple test developed for detection of protective neutralising antibodies: Infections with the coronavirus SARS-CoV-2 can take very different courses. While some people have no symptoms, others get seriously ill. [...]

    Simple test developed for detection of protective neutralising antibodies: Infections with the coronavirus SARS-CoV-2 can take very different courses. While some people have no symptoms, others get seriously ill. An important question that often arises after surviving an infection is whether neutralising antibodies against the virus have been generated. [...]

  • COVID-19: T lymphocytes play an important role

    July 17, 2020

    July 17, 2020

    July 17, 2020

    A team from Hannover Medical School, which also includes RESIST researchers, publishes the first European study of this kind in the Lancet journal "EBioMedicine‚ÄĚ / The course of infection [...]

    A team from Hannover Medical School, which also includes RESIST researchers, publishes the first European study of this kind in the Lancet journal "EBioMedicine‚ÄĚ / The course of infection [...]

    A team from Hannover Medical School, which also includes RESIST researchers, publishes the first European study of this kind in the Lancet journal "EBioMedicine‚ÄĚ / The course of infection with the coronavirus SARS-CoV-2 can progress very differently - some people recover completely without symptoms or show a mild course [...]

  • After a ‚Äúcorona break‚ÄĚ: Recruitment of RESIST cohort resumed

    June 22, 2020

    June 22, 2020

    June 22, 2020

    SARS-CoV-2 has made it very clear to us: As we age, the defense by our immune system against viruses can be very poor sometimes. Unfortunately, also vaccinations show often [...]

    SARS-CoV-2 has made it very clear to us: As we age, the defense by our immune system against viruses can be very poor sometimes. Unfortunately, also vaccinations show often [...]

    SARS-CoV-2 has made it very clear to us: As we age, the defense by our immune system against viruses can be very poor sometimes. Unfortunately, also vaccinations show often only weak effects in elderly individuals and infections can progress more severely than in younger people. Why is that? In [...]

  • SARS-CoV-2: This is what the RESIST teams are working on

    May 26, 2020

    May 26, 2020

    May 26, 2020

    Numerous RESIST scientists in the various institutions have expanded their work and are now also focusing on SARS-CoV-2: Professor Dr. Luka ńĆińćin-҆ain at the HZI is developing new technologies [...]

    Numerous RESIST scientists in the various institutions have expanded their work and are now also focusing on SARS-CoV-2: Professor Dr. Luka ńĆińćin-҆ain at the HZI is developing new technologies [...]

    Numerous RESIST scientists in the various institutions have expanded their work and are now also focusing on SARS-CoV-2: Professor Dr. Luka ńĆińćin-҆ain at the HZI is developing new technologies for improved serological virus diagnostics, for vaccine development and for identification of antiviral molecules against SARS-CoV-2. His team also works [...]

  • Particularly potent antibodies should help against SARS-CoV-2

    May 18, 2020

    May 18, 2020

    May 18, 2020

    People who have successfully mastered an infection with SARS-CoV-2 have various protective antibodies in their blood. Some of these substances are particularly effective. Detecting these highly potent antibodies, producing [...]

    People who have successfully mastered an infection with SARS-CoV-2 have various protective antibodies in their blood. Some of these substances are particularly effective. Detecting these highly potent antibodies, producing [...]

    People who have successfully mastered an infection with SARS-CoV-2 have various protective antibodies in their blood. Some of these substances are particularly effective. Detecting these highly potent antibodies, producing them genetically in the laboratory and then using them to protect against infection and to treat the disease ‚Äď this [...]

  • With smallpox vaccination vector against the new Coronavirus

    May 15, 2020

    May 15, 2020

    May 15, 2020

    In his search for a suitable vaccine against the coronavirus SARS-CoV-2, Professor F√∂rster relies on old friends. In cooperation with the Ludwig-Maximilians-Universit√§t M√ľnchen (LMU), the co-speaker of RESIST is [...]

    In his search for a suitable vaccine against the coronavirus SARS-CoV-2, Professor F√∂rster relies on old friends. In cooperation with the Ludwig-Maximilians-Universit√§t M√ľnchen (LMU), the co-speaker of RESIST is [...]

    In his search for a suitable vaccine against the coronavirus SARS-CoV-2, Professor F√∂rster relies on old friends. In cooperation with the Ludwig-Maximilians-Universit√§t M√ľnchen (LMU), the co-speaker of RESIST is testing a promising vaccine based on a smallpox virus. The Modified Vaccinia Virus Ankara (MVA) has been used as a [...]

  • RESIST-Research on the coronavirus SARS-CoV-2

    April 17, 2020

    April 17, 2020

    April 17, 2020

    Many different research projects on SARS-CoV-2 are carried out in the Cluster of Excellence RESIST - always with the aim of protecting and treating people in the best possible [...]

    Many different research projects on SARS-CoV-2 are carried out in the Cluster of Excellence RESIST - always with the aim of protecting and treating people in the best possible [...]

    Many different research projects on SARS-CoV-2 are carried out in the Cluster of Excellence RESIST - always with the aim of protecting and treating people in the best possible way. Professor Schulz gives an overview of the work: Professor Schulz, what are RESIST scientists researching with regard to SARS-CoV-2? [...]

RESIST Publications on SARS-CoV-2

  1. Persicamidines-Unprecedented Sesquarterpenoids with Potent Antiviral Bioactivity against Coronaviruses Keller L, Oueis E, Kaur A, Safaei N, Kirsch SH, Gunesch AP, Haid S, Rand U, ńĆińćin-҆ain L, Fu C, Wink J, Pietschmann T, M√ľller R. Angew Chem Int Ed Engl. 2023 Feb 1;62(6):e202214595. doi: 10.1002/anie.202214595. Epub 2023 Jan 4. PMID: 36422061; PMCID: PMC10107436.
  2. COVID-19 in pediatric lung transplant recipients: Clinical course and outcome.¬†J Heart Lung Transplant. Sch√ľtz K, Davids J, Petrik B, Zychlinsky Scharff A, Carlens J, Heim A, Salman J, Ius F, Bobylev D, Hansen G, M√ľller C, Schwerk N.¬† 2023 Apr;42(4):533-538. doi: 10.1016/j.healun.2022.11.006. Epub 2022 Dec 5. PMID: 36526496; PMCID: PMC9719846.
  3. A validated protocol to UV-inactivate SARS-CoV-2 and herpesvirus-infected cells. PLoS One. 2023 May 10;18(5):e0274065. Soh TK, Pfefferle S, Wurr S, von Possel R, Oestereich L, Rieger T, Uetrecht C, Rosenthal M, Bosse JB. PLoS One. 2023 May 10;18(5):e0274065. doi: 10.1371/journal.pone.0274065. PMID: 37163509; PMCID: PMC10171616.
  4. Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals. Barros-Martins J, Hammerschmidt SI, Morillas Ramos G, Cossmann A, Hetzel L, Odak I, K√∂hler M, Stankov MV, Ritter C, Friedrichsen M, Ravens I, Schimrock A, Ristenpart J, Janssen A, Willenzon S, Bernhardt G, Lichtinghagen R, BoŇ°njak B, Behrens GMN, F√∂rster R. Front Immunol. 2023 May 5;14:1166589.
  5. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice. Do KTH, Willenzon S, Ristenpart J, Janssen A, Volz A, Sutter G, F√∂rster R, BoŇ°njak B. Front Cell Infect Microbiol. 2023 Oct 3;13:1259822. doi: 10.3389/fcimb.2023.1259822. PMID: 37854858; PMCID: PMC10580083.
  6. Memory B cells anticipate SARS-CoV-2 variants through somatic hypermutation. Bruhn M, Obara M, Chiyyeadu A, Costa B, Salam A, Ziegler A, Waltl I, Pavlou A, Bonifacius A, Hoffmann M, Graalmann T, Pöhlmann S, Eiz-Vesper B, Schambach A, Kalinke U.  J Infect. 2024 Jan;88(1):57-60.
  7. Comparing SARS-CoV-2 variants among children and adolescents in Germany: relative risk of COVID-19-related hospitalization, ICU admission and mortality. Jank M, Oechsle AL, Armann J, Behrends U, Berner R, Chao CM, Diffloth N, Doenhardt M, Hansen G, Hufnagel M, Lander F, Liese JG, Muntau AC, Niehues T, von Both U, Verjans E, Weil K, von Kries R, Schroten H. Infection. 2023 Oct;51(5):1357-1367. doi: 10.1007/s15010-023-01996-y. Epub 2023 Feb 14. PMID: 36787015; PMCID: PMC9925936.
  8. CYP19A1 mediates severe SARS-CoV-2 disease outcome in males.¬†Stanelle-Bertram S, Beck S, Mounogou NK, Schaumburg B, Stoll F, Al Jawazneh A, Schmal Z, Bai T, Zickler M, Beythien G, Becker K, de la Roi M, Heinrich F, Schulz C, Sauter M, Krasemann S, Lange P, Heinemann A, van Riel D, Leijten L, Bauer L, van den Bosch TPP, Lopuha√§ B, Busche T, Wibberg D, Schaudien D, Goldmann T, L√ľttjohann A, Ruschinski J, Jania H, M√ľller Z, Pinho Dos Reis V, Krupp-Buzimkic V, Wolff M, Fallerini C, Baldassarri M, Furini S, Norwood K, K√§ufer C, Sch√ľtzenmeister N, von K√∂ckritz-Blickwede M, Schroeder M, Jarczak D, Nierhaus A, Welte T, Kluge S, McHardy AC, Sommer F, Kalinowski J, Krauss-Etschmann S, Richter F, von der Th√ľsen J, Baumg√§rtner W, Klingel K, Ondruschka B; GEN-COVID Multicenter Study Group; Renieri A, Gabriel G.¬† Cell Rep Med. 2023 Sep 19;4(9):101152. doi: 10.1016/j.xcrm.2023.101152. Epub 2023 Aug 12. PMID: 37572667; PMCID: PMC10518605.
  9. Genetic Predisposition to Neurological Complications in Patients with COVID-19. Biomolecules. Sahajpal NS, Hastie AR, Schieck M, Mondal AK, Felde M, van der Made CI, Chou JS, Randolph AG, Illig T, Zody MC, Brownstein CA, Beggs AH, Hoischen A, Chaubey A, Kolhe R; COVID19hostgenomesv Consortium.  2023 Jan 9;13(1):133. doi: 10.3390/biom13010133. PMID: 36671517; PMCID: PMC9855758.
  1. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. Schreiber A, Viemann D, Schöning J, Schloer S, Mecate Zambrano A, Brunotte L, Faist A, Schöfbänker M, Hrincius E, Hoffmann H, Hoffmann M, Pöhlmann S, Rescher U, Planz O, Ludwig S.  Cell Mol Life Sci. 2022 Jan 10;79(1):65.
  2. Optical genome mapping identifies rare structural variations as predisposition factors associated with severe COVID-19. Sahajpal NS, Jill Lai CY, Hastie A, Mondal AK, Dehkordi SR, van der Made CI, Fedrigo O, Al-Ajli F, Jalnapurkar S, Byrska-Bishop M, Kanagal-Shamanna R, Levy B, Schieck M, Illig T, Bacanu SA, Chou JS, Randolph AG, Rojiani AM, Zody MC, Brownstein CA, Beggs AH, Bafna V, Jarvis ED, Hoischen A, Chaubey A, Kolhe R; COVID19hostgenomesv consortium.  iScience. 2022 Jan 10:103760.
  3. Wahrnehmung der Corona-Pandemie durch Neurodermitispatienten РErgebnisse aus dem Neurodermitisregister TREATgermany. Helmert C, Siegels D, Haufe E, Abraham S, Heratizadeh A, Kleinheinz A, Harder I, Schäkel K, Effendy I, Wollenberg A, Sticherling M, Stahl M, Worm M, Schwichtenberg U, Schwarz B, Rossbacher J, Buck PM, Schenck F, Werfel T, Weidinger S, Schmitt J; das TREATgermany Studienteam. J Dtsch Dermatol Ges. 2022 Jan;20(1):45-58.
  4. Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination.¬†Hammerschmidt SI, Thurm C, BoŇ°njak B, Bernhardt G, Reinhold A, Willenzon S, Ritter C, Reinhold D, Schraven B, F√∂rster R.¬† Eur J Immunol. 2022 Feb;52(2):356-359.
  5. Dysregulated PI3K Signaling in B Cells of CVID Patients.¬†Harder I, M√ľnchhalfen M, Andrieux G, Boerries M, Grimbacher B, Eibel H, Maccari ME, Ehl S, Wienands J, Jellusova J, Warnatz K, Keller B. Cells. 2022 Jan 28;11(3):464. doi: 10.3390/cells11030464.
  6. NK cell dysfunction in severe COVID-19: TGF-ő≤-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity.¬†Barros-Martins J, F√∂rster R, BoŇ°njak B.¬† Signal Transduct Target Ther. 2022 Jan 31;7(1):32.
  7. Clinical development and approval of COVID-19 vaccines.¬†Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, T√ľreci √Ė, Pather S, Neels P.¬† Expert Rev Vaccines. 2022 Feb 14.
  8. Evolution of biofilm-adapted gene expression profiles in lasR-deficient clinical Pseudomonas aeruginosa isolates. Jeske A, Arce-Rodriguez A, Thöming JG, Tomasch J, Häussler S. NPJ Biofilms Microbiomes. 2022 Feb 14;8(1):6.
  9. Toll-like receptors matter: plasmacytoid dendritic cells in COVID-19. Becker J, Kalinke U. EMBO J. 2022 Apr 26:e111208. doi: 10.15252/embj.2022111208. Epub ahead of print.
  10. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Odak I, Schultze-Florey CR, Hammerschmidt SI, Ritter C, Willenzon S, Friedrichsen M, Ravens I, Sikora R, Bayir LM, Gutierrez Jauregui R, Bernhardt G, Stankov MV, Cossmann A, Hansen G, Krey T, Cornberg M, Koenecke C, Behrens GMN, BoŇ°njak B, F√∂rster R.¬† Front Immunol. 2022 Mar 14;13:863039. doi: 10.3389/fimmu.2022.863039. PMID: 35359969; PMCID: PMC8964088.
  11. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines.¬† Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, T√ľreci √Ė, Pather S, Neels P.¬† 2022 May;21(5):609-619.
  12. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Odak I, Schultze-Florey CR, Hammerschmidt SI, Ritter C, Willenzon S, Friedrichsen M, Ravens I, Sikora R, Bayir LM, Gutierrez Jauregui R, Bernhardt G, Stankov MV, Cossmann A, Hansen G, Krey T, Cornberg M, Koenecke C, Behrens GMN, BoŇ°njak B, F√∂rster R. Front Immunol. 2022 Mar 14;13:863039.
  13. Testing and isolation to prevent overloaded healthcare facilities and reduce death rates in the SARS-CoV-2 pandemic in Italy. Bandyopadhyay A, Schips M, Mitra T, Khailaie S, Binder SC, Meyer-Hermann M. Commun Med (Lond).
  14. The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics. Nordhorn I, Weiss D, Werfel T, Zink A, Schielein MC, Traidl S. Eur J Dermatol.
  15. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. Behrens GMN, Barros-Martins J, Cossmann A, Ramos GM, Stankov MV, Odak I, Dopfer-Jablonka A, Hetzel L, K√∂hler M, Patzer G, Binz C, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Kr√§hling V, Bernhardt G, Hoffmann M, P√∂hlmann S, Krey T, BoŇ°njak B, Hammerschmidt SI, F√∂rster R. Nat Commun. 2022 Aug 18.
  16. Hide and seek with SARS-CoV-2: spike receptor-binding domain-specific memory B cells still recognize Omicron variant.¬†Signal Transduct Target Ther. Odak I, F√∂rster R, BoŇ°njak B.¬† 2022 Oct 2;7(1):343.
  17. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults.¬†Palacios-Pedrero, M.√Ā., Jansen, J.M., Blume, C. et al. Nat Aging 2, 896‚Äď905 (2022).
  18. Binding of Glycans to the SARS CoV-2 Spike Protein, an Open Question: NMR Data on Binding Site Localization, Affinity, and Selectivity. Maass T, Ssebyatika G, Br√ľckner M, Breckwoldt L, Krey T, Mallagaray A, Peters T, Frank M, Creutznacher R. Chemistry. 2022 Dec 20;28(71):e202202614.Epub 2022 Oct 26.
  19. COVID-19 in pediatric lung transplant recipients: Clinical course and outcome. J Heart Lung Transplant. Sch√ľtz K, Davids J, Petrik B, Scharff AZ, Carlens J, Heim A, Salman J, Ius F, Bobylev D, Hansen G, M√ľller C, Schwerk N. 2022 Dec 5
  20. Altered and allele-specific open chromatin landscape reveals epigenetic and genetic regulators of innate immunity in COVID-19.¬†Zhang B, Zhang Z, Koeken VACM, Kumar S, Aillaud M, Tsay HC, Liu Z, Kraft ARM, Soon CF, Odak I, BoŇ°njak B, Vlot A; Deutsche COVID-19 OMICS Initiative (DeCOI); Swertz MA, Ohler U, Geffers R, Illig T, Huehn J, Saliba AE, Sander LE, F√∂rster R, Xu CJ, Cornberg M, Schulte LN, Li Y.¬† Cell Genom. 2022 Dec 2
  21. Association of SARS-CoV-2 Seropositivity With Myalgic Encephalomyelitis and/or Chronic Fatigue Syndrome Among Children and Adolescents in Germany. Sorg AL, Becht S, Jank M, Armann J, von Both U, Hufnagel M, Lander F, Liese JG, Niehues T, Verjans E, Wetzke M, Stojanov S, Behrends U, Drosten C, Schroten H, von Kries R.  JAMA Netw Open. 2022 Sep 1;5(9):e2233454. doi: 10.1001/jamanetworkopen.2022.33454. PMID: 36166227; PMCID: PMC9516317.
  22. Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021. Sorg AL, Bergfeld L, Jank M, Corman V, Semmler I, Goertz A, Beyerlein A, Verjans E, Wagner N, Von Bernuth H, Lander F, Weil K, Hufnagel M, Spiekerkoetter U, Chao CM, Naehrlich L, Muntau AC, Schulze-Sturm U, Hansen G, Wetzke M, Jung AM, Niehues T, Fricke-Otto S, Von Both U, Huebner J, Behrends U, Liese JG, Schwerk C, Drosten C, Von Kries R, Schroten H.  Nat Commun. 2022 Jun 6;13(1):3128. doi: 10.1038/s41467-022-30482-6. PMID: 35668073; PMCID: PMC9170697.
  23. Differential interferon-őĪ subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.¬†Schuhenn J, Meister TL, Todt D, Bracht T, Schork K, Billaud JN, Elsner C, Heinen N, Karakoese Z, Haid S, Kumar S, Brunotte L, Eisenacher M, Di Y, Lew J, Falzarano D, Chen J, Yuan Z, Pietschmann T, Wiegmann B, Uebner H, Taube C, Le-Trilling VTK, Trilling M, Krawczyk A, Ludwig S, Sitek B, Steinmann E, Dittmer U, Lavender KJ, Sutter K, Pfaender S.¬† Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):e2111600119. doi: 10.1073/pnas.2111600119. PMID: 35131898; PMCID: PMC8872780.
  24. Effects of Pre-Existing Mental Conditions on Fatigue and Psychological Symptoms Post-COVID-19.¬†Homann S, Mikuteit M, Niewolik J, Behrens GMN, St√∂lting A, M√ľller F, Schr√∂der D, Heinemann S, M√ľllenmeister C, El-Sayed I, Happle C, Steffens S, Dopfer-Jablonka A. Int J Environ Res Public Health. 2022 Aug 11;19(16):9924. doi: 10.3390/ijerph19169924. PMID: 36011559; PMCID: PMC9408008.
  25. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Odak I, Schultze-Florey CR, Hammerschmidt SI, Ritter C, Willenzon S, Friedrichsen M, Ravens I, Sikora R, Bayir LM, Gutierrez Jauregui R, Bernhardt G, Stankov MV, Cossmann A, Hansen G, Krey T, Cornberg M, Koenecke C, Behrens GMN, BoŇ°njak B, F√∂rster R.¬† Front Immunol. 2022 Mar 14;13:863039. doi: 10.3389/fimmu.2022.863039. PMID: 35359969; PMCID: PMC8964088.
  26. SARS-CoV-2 Viral Load in the Pulmonary Compartment of Critically Ill COVID-19 Patients Correlates with Viral Serum Load and Fatal Outcomes.¬†Ynga-Durand M, Maa√ü H, MiloŇ°evińá M, Krstanovińá F, Pribanińá MateŇ°ińá M, Jonjińá S, Protińá A, Brizińá I, ҆ustińá A, ńĆińćin-҆ain L.¬† Viruses. 2022 Jun 14;14(6):1292. doi: 10.3390/v14061292. PMID: 35746764; PMCID: PMC9228931.
  27. The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines.¬†McLean G, Kamil J, Lee B, Moore P, Schulz TF, Muik A, Sahin U, T√ľreci √Ė, Pather S. mBio. 2022 Apr 26;13(2):e0297921. doi: 10.1128/mbio.02979-21. Epub 2022 Mar 30. PMID: 35352979; PMCID: PMC9040821.
  1. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.¬†Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, M√ľnch J, Hoffmann M, P√∂hlmann S, Krey T, BoŇ°njak B, F√∂rster R, Behrens GMN. Nat Med. 2021 Jul 14. doi: 10.1038/s41591-021-01449-9. Online ahead of print. PMID: 34262158
  2. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Hammerschmidt SI, Bosnjak B, Bernhardt G, Friedrichsen M, Ravens I, Dopfer-Jablonka A, Hoffmann M, Pöhlmann S, Behrens GMN, Förster R. Cell Mol Immunol. 2021 Oct;18(10):2455-2456. doi: 10.1038/s41423-021-00755-z. Epub 2021 Aug 23. PMID: 34426672; PMCID: PMC8381713.
  3. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.¬†Tscherne A, Schwarz JH, Rohde C, Kupke A, Kalodimou G, Limpinsel L, Okba NMA, BoŇ°njak B, Sandrock I, Odak I, Halwe S, Sauerhering L, Brosinski K, Liangliang N, Duell E, Jany S, Freudenstein A, Schmidt J, Werner A, Gellhorn Serra M, Kl√ľver M, Guggemos W, Seilmaier M, Wendtner CM, F√∂rster R, Haagmans BL, Becker S, Sutter G, Volz A. Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):e2026207118. doi: 10.1073/pnas.2026207118. PMID: 34162739 Free PMC article.
  4. Development of the reproduction number from coronavirus SARS-CoV-2 case data in Germany and implications for political measures. Khailaie S, Mitra T, Bandyopadhyay A, Schips M, Mascheroni P, Vanella P, Lange B, Binder SC, Meyer-Hermann M. BMC Med. 2021 Jan 28;19(1):32. doi: 10.1186/s12916-020-01884-4. PMID: 33504336 Free PMC article.
  5. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy.¬†BoŇ°njak B, Odak I, Ritter C, Stahl K, Graalmann T, Steinbr√ľck L, Blasczyk R, Falk CS, Schulz TF, Wedemeyer HH, Cornberg M, Ganser A, F√∂rster R, Koenecke C. Front Immunol. 2021 Aug 12;12:721738
  6. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.¬†BoŇ°njak B, Odak I, Barros-Martins J, Sandrock I, Hammerschmidt SI, Permanyer M, Patzer GE, Greorgiev H, Gutierrez Jauregui R, Tscherne A, Schwarz JH, Kalodimou G, Ssebyatika G, Ciurkiewicz M, Willenzon S, Bubke A, Ristenpart J, Ritter C, Tuchel T, Meyer Zu Natrup C, Shin DL, Clever S, Limpinsel L, Baumg√§rtner W, Krey T, Volz A, Sutter G, F√∂rster R. Front Immunol. 2021 Nov 11;12:772240.
  7. Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination.¬†Hammerschmidt SI, Thurm C, BoŇ°njak B, Bernhardt G, Reinhold A, Willenzon S, Ritter C, Reinhold D, Schraven B, F√∂rster R. Eur J Immunol. 2021 Dec 6.
  8. Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality? Gussarow D, Bonifacius A, Cossmann A, Stankov MV, Mausberg P, Tischer-Zimmermann S, Gödecke N, Kalinke U, Behrens GMN, Blasczyk R, Eiz-Vesper B. Front Med (Lausanne). 2021 Nov 25;8:770381.
  9. Conservation of the HBV RNA element epsilon in nackednaviruses reveals ancient origin of protein-primed reverse transcription. Beck J, Seitz S, Lauber C, Nassal M. Proceedings of the National Academy of Sciences 2021.
  10. Discrimination of SARS-CoV-2 Infections From Other Viral Respiratory Infections by Scent Detection Dogs. Ten Hagen NA, Twele F, Meller S, Jendrny P, Schulz C, von Köckritz-Blickwede M, Osterhaus A, Ebbers H, Pink I, Welte T, Manns MP, Illig T, Fathi A, Addo MM, Nitsche A, Puyskens A, Michel J, Krause E, Ehmann R, von Brunn A, Ernst C, Zwirglmaier K, Wölfel R, Nau A, Philipp E, Engels M, Schalke E, Volk HA. Front Med (Lausanne). 2021 Nov 18;8:749588. doi: 10.3389/fmed.2021.749588. PMID: 34869443; PMCID: PMC8636992.
  11. Early IFN-őĪ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19.¬†Kr√§mer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-Garc√≠a R, Schulte-Schrepping J, Kaiser KM, Rieke GJ, Bischoff J, Monin MB, Hoffmeister C, Schlabe S, De Domenico E, Reusch N, H√§ndler K, Reynolds G, Bl√ľthgen N, Hack G, Finnemann C, Nischalke HD, Strassburg CP, Stephenson E, Su Y, Gardner L, Yuan D, Chen D, Goldman J, Rosenstiel P, Schmidt SV, Latz E, Hrusovsky K, Ball AJ, Johnson JM, Koenig PA, Schmidt FI, Haniffa M, Heath JR, K√ľmmerer BM, Keitel V, Jensen B, Stubbemann P, Kurth F, Sander LE, Sawitzki B; Deutsche COVID-19 OMICS Initiative (DeCOI); Aschenbrenner AC, Schultze JL, Nattermann J. Immunity. 2021 Nov 9;54(11):2650-2669.e14. doi: 10.1016/j.immuni.2021.09.002. Epub 2021 Sep 4. PMID: 34592166; PMCID: PMC8416549.
  12. Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks.¬†Ruhl L, Pink I, K√ľhne JF, Beushausen K, Keil J, Christoph S, Sauer A, Boblitz L, Schmidt J, David S, J√§ck HM, Roth E, Cornberg M, Schulz TF, Welte T, H√∂per MM, Falk CS. Signal Transduct Target Ther. 2021 Dec 10;6(1):418. doi: 10.1038/s41392-021-00819-6. PMID: 34893580; PMCID: PMC8661333.
  13. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Becker M, Strengert M, Junker D, Kaiser PD, Kerrinnes T, Traenkle B, Dinter H, Häring J, Ghozzi S, Zeck A, Weise F, Peter A, Hörber S, Fink S, Ruoff F, Dulovic A, Bakchoul T, Baillot A, Lohse S, Cornberg M, Illig T, Gottlieb J, Smola S, Karch A, Berger K, Rammensee HG, Schenke-Layland K, Nelde A, Märklin M, Heitmann JS, Walz JS, Templin M, Joos TO, Rothbauer U, Krause G, Schneiderhan-Marra N.  Nat Commun. 2021 Feb 19;12(1):1152. doi: 10.1038/s41467-021-20973-3. PMID: 33608538; PMCID: PMC7896075.
  14. Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease.¬†Ricke-Hoch M, Stelling E, Lasswitz L, Gunesch AP, Kasten M, Zapatero-Belinch√≥n FJ, Brogden G, Gerold G, Pietschmann T, Montiel V, Balligand JL, Facciotti F, Hirsch E, Gausepohl T, Elbahesh H, Rimmelzwaan GF, H√∂fer A, K√ľhnel MP, Jonigk D, Eigendorf J, Tegtbur U, Mink L, Scherr M, Illig T, Schambach A, Pfeffer TJ, Hilfiker A, Haverich A, Hilfiker-Kleiner D.¬† PLoS One. 2021 Aug 4;16(8):e0255335. doi: 10.1371/journal.pone.0255335. PMID: 34347801; PMCID: PMC8336874.
  15. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP).¬†Horn A, Krist L, Lieb W, Montellano FA, Kohls M, Haas K, Gelbrich G, Bolay-Gehrig SJ, Morbach C, Reese JP, St√∂rk S, Fricke J, Zoller T, Schmidt S, Triller P, Kretzler L, R√∂nnefarth M, Von Kalle C, Willich SN, Kurth F, Steinbeis F, Witzenrath M, Bahmer T, Hermes A, Krawczak M, Reinke L, Maetzler C, Franzenburg J, Enderle J, Flinspach A, Vehreschild J, Schons M, Illig T, Anton G, Ungeth√ľm K, Finkenberg BC, Gehrig MT, Savaskan N, Heuschmann PU, Keil T, Schreiber S.¬† Infection. 2021 Dec;49(6):1277-1287. doi: 10.1007/s15010-021-01707-5. Epub 2021 Oct 12. PMID: 34642875; PMCID: PMC8508400.
  16. Mapping the human genetic architecture of COVID-19. COVID-19 Host Genetics Initiative. Nature. 2021 Dec;600(7889):472-477. doi: 10.1038/s41586-021-03767-x. Epub 2021 Jul 8. PMID: 34237774; PMCID: PMC8674144.
  17. Neurological symptoms and complications in predominantly hospitalized COVID-19 patients: Results of the European multinational Lean European Open Survey on SARS-Infected Patients (LEOSS).¬†Kleineberg NN, Knauss S, G√ľlke E, Pinnschmidt HO, Jakob CEM, Lingor P, Hellwig K, Berthele A, H√∂glinger G, Fink GR, Endres M, Gerloff C, Klein C, Stecher M, Classen AY, Rieg S, Borgmann S, Hanses F, R√ľthrich MM, Hower M, Tometten L, Haselberger M, Piepel C, Merle U, Dolff S, Degenhardt C, Jensen BO, Vehreschild MJGT, Erber J, Franke C, Warnke C; LEOSS Study Group.¬† Eur J Neurol. 2021 Dec;28(12):3925-3937. doi: 10.1111/ene.15072. Epub 2021 Sep 3. PMID: 34411383; PMCID: PMC8444823.
  18. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, Donnerstag F, Weißenborn K, Höglinger G, Maasoumy B, Wedemeyer H, Ganser A. Blood. 2021 Jul 29;138(4):350-353. doi: 10.1182/blood.2021011958. PMID: 34323939; PMCID: PMC8084604.
  19. Swarm Learning for decentralized and confidential clinical machine learning.¬†Warnat-Herresthal S, Schultze H, Shastry KL, Manamohan S, Mukherjee S, Garg V, Sarveswara R, H√§ndler K, Pickkers P, Aziz NA, Ktena S, Tran F, Bitzer M, Ossowski S, Casadei N, Herr C, Petersheim D, Behrends U, Kern F, Fehlmann T, Schommers P, Lehmann C, Augustin M, Rybniker J, Altm√ľller J, Mishra N, Bernardes JP, Kr√§mer B, Bonaguro L, Schulte-Schrepping J, De Domenico E, Siever C, Kraut M, Desai M, Monnet B, Saridaki M, Siegel CM, Drews A, Nuesch-Germano M, Theis H, Heyckendorf J, Schreiber S, Kim-Hellmuth S; COVID-19 Aachen Study (COVAS); Nattermann J, Skowasch D, Kurth I, Keller A, Bals R, N√ľrnberg P, Rie√ü O, Rosenstiel P, Netea MG, Theis F, Mukherjee S, Backes M, Aschenbrenner AC, Ulas T; Deutsche COVID-19 Omics Initiative (DeCOI); Breteler MMB, Giamarellos-Bourboulis EJ, Kox M, Becker M, Cheran S, Woodacre MS, Goh EL, Schultze JL.¬† Nature. 2021 Jun;594(7862):265-270. doi: 10.1038/s41586-021-03583-3. Epub 2021 May 26. PMID: 34040261; PMCID: PMC8189907.
  20. The Upper Respiratory Tract of Felids Is Highly Susceptible to SARS-CoV-2 Infection.¬†Kr√ľger N, Rocha C, Runft S, Kr√ľger J, F√§rber I, Armando F, Leitzen E, Brogden G, Gerold G, P√∂hlmann S, Hoffmann M, Baumg√§rtner W.¬† Int J Mol Sci. 2021 Sep 30;22(19):10636. doi: 10.3390/ijms221910636. PMID: 34638978; PMCID: PMC8508926.
  21. Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch.¬†O‚ÄôToole √Ā, Hill V, Pybus OG, Watts A, Bogoch II, Khan K, Messina JP; COVID-19 Genomics UK (COG-UK) consortium; Network for Genomic Surveillance in South Africa (NGS-SA); Brazil-UK CADDE Genomic Network; Tegally H, Lessells RR, Giandhari J, Pillay S, Tumedi KA, Nyepetsi G, Kebabonye M, Matsheka M, Mine M, Tokajian S, Hassan H, Salloum T, Merhi G, Koweyes J, Geoghegan JL, de Ligt J, Ren X, Storey M, Freed NE, Pattabiraman C, Prasad P, Desai AS, Vasanthapuram R, Schulz TF, Steinbr√ľck L, Stadler T; Swiss Viollier Sequencing Consortium; Parisi A, Bianco A, Garc√≠a de Viedma D, Buenestado-Serrano S, Borges V, Isidro J, Duarte S, Gomes JP, Zuckerman NS, Mandelboim M, Mor O, Seemann T, Arnott A, Draper J, Gall M, Rawlinson W, Deveson I, Schlebusch S, McMahon J, Leong L, Lim CK, Chironna M, Loconsole D, Bal A, Josset L, Holmes E, St George K, Lasek-Nesselquist E, Sikkema RS, Oude Munnink B, Koopmans M, Brytting M, Sudha Rani V, Pavani S, Smura T, Heim A, Kurkela S, Umair M, Salman M, Bartolini B, Rueca M, Drosten C, Wolff T, Silander O, Eggink D, Reusken C, Vennema H, Park A, Carrington C, Sahadeo N, Carr M, Gonzalez G; SEARCH Alliance San Diego; National Virus Reference Laboratory; SeqCOVID-Spain; Danish Covid-19 Genome Consortium (DCGC); Communicable Diseases Genomic Network (CDGN); Dutch National SARS-CoV-2 surveillance program; Division of Emerging Infectious Diseases (KDCA); de Oliveira T, Faria N, Rambaut A, Kraemer MUG. Wellcome Open Res. 2021 Sep 17;6:121. doi: 10.12688/wellcomeopenres.16661.2. PMID: 34095513; PMCID: PMC8176267.
  1. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) ‚Äď protocol for a multi-center, single-arm phase IIa trial.¬†Frye BC, Rump IC, Uhlmann A, Schubach F, Ihorst G, Grimbacher B, Zissel G, Quernheim JM.Contemp Clin Trials Commun. 2020 May 29;19:100575. doi: 10.1016/j.conctc.2020.100575. PMID: 32551397; PMCID: PMC7292904.
  2. Reappearance of effector T cells is associated with recovery from COVID-19. EBioMedicine. 2020 Jul;57:102885. doi: 10.1016/j.ebiom.2020.102885. Epub 2020 Jul 7. PMID: 32650275; PMCID: PMC7338277. Odak I, Barros-Martins J, BoŇ°njak B, Stahl K, David S, Wiesner O, Busch M, Hoeper MM, Pink I, Welte T, Cornberg M, Stoll M, Goudeva L, Blasczyk R, Ganser A, Prinz I, F√∂rster R, Koenecke C, Schultze-Florey CR.
  3. Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung. Förster R, Fleige H, Sutter G. Front Immunol. 2020 Aug 7;11:1959. doi: 10.3389/fimmu.2020.01959. PMID: 32849655; PMCID: PMC7426738.
  4. Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. Behrens GMN, Cossmann A, Stankov MV, Schulte B, Streeck H, Förster R, Bosnjak B, Willenzon S, Boeck AL, Thu Tran A, Thiele T, Graalmann T, Kayser MZ, Zychlinsky Scharff A, Dopfer C, Horke A, Pink I, Witte T, Wetzke M, Ernst D, Jablonka A, Happle C. Infect Dis Ther. 2020 Dec;9(4):837-849. doi: 10.1007/s40121-020-00334-1. Epub 2020 Sep 4. PMID: 32886335; PMCID: PMC7472691.
  5. COVID-19 related reduction in pediatric emergency healthcare utilization ‚Äď a concerning trend.¬†Dopfer C, Wetzke M, Zychlinsky Scharff A, Mueller F, Dressler F, Baumann U, Sasse M, Hansen G, Jablonka A, Happle C. BMC Pediatr. 2020 Sep 7;20(1):427. doi: 10.1186/s12887-020-02303-6. PMID: 32894080; PMCID: PMC7475725.
  6. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.¬†BoŇ°njak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, Ravens I, Ritter C, Schultze-Florey CR, G√∂decke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A, Yilmaz M, Pink I, Hoeper MM, Behrens GMN, P√∂hlmann S, Blasczyk R, Schulz TF, F√∂rster R.¬† Cell Mol Immunol. 2020 Nov 2:1‚Äď9. doi: 10.1038/s41423-020-00573-9. Epub ahead of print. PMID: 33139905; PMCID: PMC7604543.
  7. Double-edge anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods Bosnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, Ravens I, Ritter C, Schultze-Florey CR, Gödecke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A, Yilmaz M, Pink I, Hoeper MM, Behrens GMN, Pöhlmann S, Blasczyk R, Schulz TF, Forster R.  Cell Mol Immunol 2020
  8. A call for a global COVID-19 Neuro Research Coalition. Winkler AS, Knauss S, Schmutzhard E, Leonardi M, Padovani A, Abd-Allah F, Charway-Felli A, Emmrich JV, Umapathi T, Satishchandra P, Hoo FK, Dalmau J, Oreja-Guevara C, Ferreira MLB, Pfausler B, Michael BD, Tagliavini F, Höglinger G, Endres M, Klein C, Hemmer B, Carroll W, Sejvar J, Solomon T. Lancet Neurol. 2020 Jun;19(6):482-484. doi: 10.1016/S1474-4422(20)30150-2. Epub 2020 May 26. Erratum in: Lancet Neurol. 2020 Aug;19(8):e7. PMID: 32470416; PMCID: PMC7250549.
  9. A molecular pore spans the double membrane of the coronavirus replication organelle.¬†Wolff G, Limpens RWAL, Zevenhoven-Dobbe JC, Laugks U, Zheng S, de Jong AWM, Koning RI, Agard DA, Gr√ľnewald K, Koster AJ, Snijder EJ, B√°rcena M. Science. 2020 Sep 11;369(6509):1395-1398. doi: 10.1126/science.abd3629. Epub 2020 Aug 6. PMID: 32763915; PMCID: PMC7665310.
  10. Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient. Huber M, Rogozinski S, Puppe W, Framme C, Höglinger G, Hufendiek K, Wegner F.  Front Neurol. 2020 Oct 6;11:576153. doi: 10.3389/fneur.2020.576153. PMID: 33123081; PMCID: PMC7573137.